

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

Appl. No. 09/927,006
Amdt. Dated December 9, 2003
Reply to Office Action of July 11, 2003

Amendments to the Claims:

This listing will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (currently amended): A peptide or its derivative having anti-angiogenic functionality of the structure:

Arg-Asn-Pro-Asp-Gly-Asp-Ile-Asn-Gly-Pro-Trp (hereinafter referred to as {4}),

or

Trp-Pro-Gly-Asn-Ile-Asp-Gly-Asp-Pro-Asn-Arg (hereinafter referred to as {4'}),

or

Tyr-Thr-Met-Asn-Pro-Arg-Lys-Leu-Phe-Asp-Tyr (hereinafter referred to as {5}),

or

Tyr-Asp-Phe-Leu-Lys-Arg-Pro-Asn-Met-Thr-Tyr (hereinafter referred to as {5'}),

or

X-{4}-Y

or

X-{4'}-Y

or

Appl. No. 09/927,006
Amdt. Dated December 9, 2003
Reply to Office Action of July 11, 2003

X-{5}-Y

or

X-{5'}-Y

or

X-{4}-Ala-{5}-Y

or

X-{4'}-Ala-{5'}-Y

or

X-{5}-Ala-{4}-Y

or

~~X-{5}-Ala-{4}-Y~~ X-{5'}-Ala-{4'}-Y

or

X-{4}-Cys-{5'}-Y

or

X-{4'}-Cys-{5'}-Y

or

X-{5}-Cys-{4}-Y

or

X-{5'}-Cys-{4'}-Y

or

Appl. No. 09/927,006
Amtd. Dated December 9, 2003
Reply to Office Action of July 11, 2003

$X-\{4\}-(\text{Gly-Gly-Gly-Ser})_n-\{5\}-Y$

or

$X-\{4'\}-(\text{Gly-Gly-Gly-Ser})_n-\{5'\}-Y$

or

$X-\{5\}-(\text{Gly-Gly-Gly-Ser})_n-\{4\}-Y$

or

$\text{Cys}-\{4\}-\text{Ala}-\{5\}-\text{Cys}$

or

$\text{Cys}-\{4'\}-\text{Ala}-\{5'\}-\text{Cys}$

or

$\text{Cys}-\{5\}-\text{Ala}-\{4\}-\text{Cys}$

or

$\text{Cys}-\{5'\}-\text{Ala}-\{4'\}-\text{Cys}$

or

$\text{Ala}-\{4\}-\text{Ala}-\{5\}-\text{Ala}$

Appl. No. 09/927,006
Amdt. Dated December 9, 2003
Reply to Office Action of July 11, 2003

or

Ala-{4'}-Ala-{5'}-Ala

or

Ala-{5'}-Ala-{4'}-Ala

or

Ala-{5'}-Ala-{4'}-Ala

wherein the sequence of amino acids is written from the N-terminus (on the left) to the C-terminus (on the right);

wherein X is Acetyl group or other customary N-terminal protecting groups;

wherein y is amine, ethylamine, or other customary C-terminal protecting groups;

wherein n= 1 to 3.

Claim 2 (currently amended): A pharmaceutical composition comprising at least one or a plurality of said ~~peptide~~ peptides or ~~its~~ peptide derivatives ~~in~~ of claim 1.

Claim 3 (currently amended): ~~Said A~~ A peptide or its derivative ~~in~~ according to claim ~~1~~ 1, wherein at least one or a plurality of amino acids of said peptide or derivative is ~~are~~ in a D-form.

Appl. No. 09/927,006
Amdt. Dated December 9, 2003
Reply to Office Action of July 11, 2003

Claim 4 (currently amended): A pharmaceutical composition comprising ~~one or a plurality~~ at least one of said ~~peptide or its~~ peptides or derivatives in of claim 3.

Claim 5 (currently amended): Said A peptide or its derivative in according to claim ~~1~~ 1, wherein one amino acid is removed, replaced, or added to said peptide or derivative to form a new molecule.

Claim 6 (currently amended): A pharmaceutical ~~products~~ produce comprising at least one or a plurality of said ~~peptide~~ peptides or its derivatives in of claim 5.

Claim 7 (currently amended): ~~Said A~~ A peptide or its derivative in according to claim ~~1~~ 1, wherein either the ~~a~~ C-terminal protecting group or the ~~an~~ N-terminal protecting group is removed ~~if there is~~ any: from the peptide or derivative.

Claim 8 (currently amended): A pharmaceutical product comprising ~~one or a plurality~~ at least one of said ~~peptide or its derivative in~~ peptides or derivatives of claim 7.

Claim 9 (original): A method for the treatment of diseases related to angiogenesis by administering to a patient a therapeutic amount of said peptides or its derivatives in claim 1.

Appl. No. 09/927,006
Amdt. Dated December 9, 2003
Reply to Office Action of July 11, 2003

Claim 10 (original): The method in claim 9 wherein said diseases comprises lung cancer, liver cancer, brain cancer, colon cancer, impairment of vision induced by late-stage diabetes, and other diseases related to angiogenesis.

Claim 11 (original): A method for the treatment of diseases related to angiogenesis by administering to a patient a pharmaceutical composition comprising of said peptides or its derivatives in claim 1.

Claim 12 (original): The method in claim 11 wherein said diseases comprises lung cancer, liver cancer, brain cancer, colon cancer, impairment of vision induced by late-stage diabetes, and other diseases related to angiogenesis.